Vaccine market expands in China
The report shows that in 2012 the human vaccine market in China was valued at RMB 10.5 billion, with a lot release quantity of approximately 773 million person-portions. This market was affected by China's restricted policies and conditions that allowed for a strong EPI market to be monopolized by state-run enterprises like CNBG Tiantan Biological and Biological Products Institutes in Changchun. The state-owned enterprises seized much of the EPI vaccine market, taking 81.5 percent of the vaccine lot.
Due to a gradual relaxation of China's control over the EPI market, Foreign counterparts to the EPI market were able to take a considerable market share. In 2012, private and foreign-funded enterprises occupied 49.9 percent and 22.1 percent of Chinese Extra EPI vaccine market.
The report also reviews some notable achievements seen in China in 2012. By the end of 2012, the first batch of the Hib vaccine products, made by Walvax Biotechnology, were approved by China Customs and exported to Manila. Also in 2012, Xiamen University and YangShengTang INNOVAX created the world's first industrialization of a recombinant hepatitis E vaccine.